Navigation Links
Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
Date:2/4/2008

NEW YORK, Feb. 4 /PRNewswire/ -- There is a large and growing "treatment gap" between the number of patients worldwide who would benefit from an organ transplant and the number of organs available, a gap that is impacting transplant medicine markets, according to a new market research report from Kalorama Information, Organ Transplant Immunosuppressive Markets.

In the US, over 97,000 patients were on the United Network for Organ Sharing's list, while just 28,000 received a transplant. Other countries show similar gaps. This gap was first evident in 1998 and has increased every year.

Immunosuppressives, drugs which prevent the immune system from rejecting a new organ, may have become victims of their own success. Medicines such as Astella's Prograf and Roche's CellCept have reduced incidence of acute organ rejection and made transplantation a viable option in more cases, thus increased organ waiting lists. Kidney acute rejection rates alone decreased from 51% in 1996 to 13% eight years later as a result of these therapies. Over $5 billion worth of these drugs were sold in 2007.

"The pharmaceutical industry has created effective medications, and now the challenge is in the public policy arena," said Bruce Carlson, Publisher of Kalorama Information. "Awareness of the need for organ donation must be increased for the demand to be completely served. Volunteer efforts towards more organ donation have so far not been sufficient."

Despite the shortage, the study indicates that the marketplace for immunosuppressives will still grow at nearly five percent for the next five years due to a small increase in transplant operations and increased survival rates of patients who will require treatment for a longer period. But the study stresses that solving the donor shortage would lead to exponential growth in transplant medicine markets.

Organ Transplant Immunosuppressive Markets provides detailed statistics, market size and forecasts, trends and competitive analysis for kidney, liver, lung, heart and intestine transplants. This report can be purchased directly from Kalorama Information by visiting http://www.kaloramainformation.com/Organ-Transplant-Immunosuppressive-13995 27/

About Kalorama Information

Kalorama Information supplies the latest in independent market research for the life sciences and a full range of custom research services. For more information, contact Tom Ehart at 240-747-3014 or tehart@marketresearch.com, or visit http://www.KaloramaInformation.com.


'/>"/>
SOURCE Kalorama Information
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
2. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
3. Grammy Winner Marc Cohn to Perform for African AIDS Organization at Carolina HopeFest
4. Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference
5. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
6. UCLA Program Aims to Revolutionize Kidney Transplants
7. Sexual Function Affected by Stem Cell Transplant According to Long-Term Study
8. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
9. Improved Cornea Surgery Technique Provides Enhanced Transplant Success
10. Allegheny General Hospital Performs First Liver Transplant
11. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/23/2017)... Sept. 22, 2017 Janssen Biotech, Inc. (Janssen) ... letter from the U.S. Food and Drug Administration (FDA) ... sirukumab for the treatment of moderately to severely active ... clinical data are needed to further evaluate the safety ... active RA. ...
(Date:9/19/2017)... ANN ARBOR, Mich. , Sept. 19, 2017 HistoSonics, Inc., a venture-backed medical ... the precise destruction of targeted tissues, announced three leadership team developments today:   ... Josh Stopek, PhD ... ... Veteran medical device executive ...
Breaking Medicine Technology:
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... 13, 2017 , ... Many families have long-term insurance that covers care for ... a waiver for care if the client has a cognitive impairment diagnosis. , ... care, is often waived, so the benefits from their insurance start immediately,” said Mechell ...
(Date:10/13/2017)... ... 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... popular and least understood books in the Holy Scriptures, Revelation. The Book of Revelation ... scholars for centuries. Many have tossed it off as mere rubbish, but Yisrayl Hawkins ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
Breaking Medicine News(10 mins):